SARS-COV2 Pandemic Serosurvey and Blood Sampling
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Matthew J Memoli, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama
Birmingham, Alabama, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Aug 2020
- Primary completion
- 31 Dec 2021
- Completion
- 21 Jan 2022
- Last update posted
- 26 Jan 2024
- Registered enrollment
- 11,363
- Registry id
- NCT04334954
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.